logo
Plus   Neg
Share
Email

Roche: Port Delivery System With Ranibizumab Shows Positive Trial Results In NAMD

Swiss drug maker Roche (RHHBY) announced Wednesday positive topline results from the phase III Archway study, evaluating Port Delivery System with ranibizumab in people living with neovascular or "wet" age-related macular degeneration or nAMD.

Port Delivery System with ranibizumab or PDS is a permanent refillable eye implant, approximately the size of a grain of rice, which continuously delivers a customised formulation of ranibizumab over a period of months.

The company noted that the Archway trial met its primary endpoint, demonstrating that patients with PDS who received refills every six months achieved visual acuity outcomes equivalent to those receiving monthly ranibizumab 0.5 mg injections.

In Archway, PDS was generally well-tolerated with a favorable benefit-risk profile.

Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development, said, "For people around the world receiving frequent eye injections for neovascular AMD, this continuous delivery system could greatly reduce their treatment burden."

The company expects to present detailed Archway results at an upcoming medical meeting and to submit to regulatory authorities across the world.

The Portal study is also investigating the long-term safety and tolerability of PDS for the treatment of nAMD. PDS is also being studied in the Pagoda trial for the treatment of diabetic macular edema or DME, a vision-threatening complication of diabetes.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
U.S. retailers Best Buy Co. Inc., Abercrombie & Fitch Co., and Dollar Tree Inc. on Tuesday reported results for the third quarter that surpassed analysts' expectations. The upbeat results indicate that retailers have largely recovered from the impact of the coronavirus pandemic just as the holiday season approaches. The companies have also intensified their focused on digital sales. The U.S. Food and Drug Administration approved the first drug to treat primary hyperoxaluria type 1 (PH1), an ultra-rare genetic disorder which causes recurrent kidney stones and loss of kidney function. Alnylam Pharmaceuticals' Oxlumo (lumasiran) in the form of injection lowers urinary oxalate levels in pediatric and adult patients. The U.S. federal government's General Services Administration or GSA has awarded a five-year federal transportation contract, estimated to be worth up to $810 million, to Uber Technologies Inc. and Lyft Inc., according to multiple reports. Under the contract, the ride-hailing companies would provide services to various public agencies and their around 4 million employees across the nation.
Follow RTT